Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. (Optimise)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 19, 2008
Last updated: June 1, 2010
Last verified: June 2010

Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • HbA1c, LDL-cholesterol, Systolic Blood Pressure [ Time Frame: Visit 1; Visit 2 (after approximately 4 months after visit 1); Visit 3 (after approximately 8 months after visit 1); Visit 4 (after approximately 12 months after visit 1) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice [ Time Frame: Visit 1Visit 2 (after approximately 4 months after visit 1)Visit 3 (after approximately 8 months after visit 1)Visit 4 (after approximately 12 months after visit 1) ] [ Designated as safety issue: No ]

Enrollment: 4027
Study Start Date: March 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Control group
Benchmarking group


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

General Practioners


Inclusion Criteria:

  • Provision of informed Consent
  • Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

Exclusion Criteria:

  • Type I diabetes
  • Pregnancy diabetes
  • Hospitalisation, as this is a primary care study
  • Patients who are member of the Belgian Diabetes Convention
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00681850

  Show 252 Study Locations
Sponsors and Collaborators
Principal Investigator: Hermans, M. Prof. UCL
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eugène Vissers, MD, Therapeutic Area Leader Cardivascular and Diabetes., AstraZeneca Pharmaceuticals Identifier: NCT00681850     History of Changes
Other Study ID Numbers: D3560L00071
Study First Received: May 19, 2008
Last Updated: June 1, 2010
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
quality of patient care
Diabetic Population

Additional relevant MeSH terms:
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases processed this record on February 27, 2015